The Psychiatric Disease Pipeline: A Strategic Review

Published by	Decision Resources, Inc.
Published	July, 2009	Product code	95281
Content info	27 Pages
Price	US $ 4600 PDF by E-mail (Global License)

Introduction
Related Reports

The Psychiatric Disease Pipeline: A Strategic Review published by Decision Resources, Inc. in July, 2009. This report consists of 27 Pages and the price starts from US $ 4600.

Introduction

Abstract

Introduction

Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications, 28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in recent years, sustained franchise sales, tolerance for use of multiple drugs within a drug class, and a clinical pipeline of more than 150 agents. Given the heterogeneity of the patient populations in the psychiatric disease sector, unmet need and commercial opportunity are high. We explore ways in which companies are using strategic differentiation and novel targets to overcome challenges and tap sales potential.

Questions Answered in This Report

A database search of agents in development for psychiatric disease yields nearly 300 agents. From this list, we have confi rmed that more than 150 of the agents are still in clinical development for psychiatric diseases. What are the most common indication and mechanism targets of development? How advanced is the pipeline overall? What companies are most active in psychiatric drug development?
Unmet needs create opportunities for emerging agents. What are the unmet needs specifi c to psychiatric indications? Are there any drugs in the pipeline that promise to address these unmet needs?
Eli Lilly leads the psychiatric sector in terms of sales; GlaxoSmithKline (GSK), another sales leader, stands out with the largest pipeline; and AstraZeneca (AZ) is notable for being a sales leader with just one marketed psychiatric disease agent. What accounts for the success of these companies to date? How are they defending their leadership positions? What other companies are vying for prime positions in this sector?
With many drugs on the market and many of them available g enerically, competition is intense in this marketplace. What strategies have companies used to preserve patient share and market share? How are makers of emerging agents likely to position their products?

Scope

2008 market: 2008 sales; leading drug classes; market-leading companies; commercial position of leading agents.
Psychiatric disease pipeline: number of agents in development; disease focus; active companies; profi les of GSK and AZ; mechanisms of action; company type; phase analysis; novel formulations versus reformulations.
Psychiatric diseases focused on in this report: schizophrenia; depression; anxiety; addiction; attention-defi cit/hyperactivity disorder (ADHD); cognitive impairment associated with schizophrenia (CIAS).
Opportunities in psychiatric diseases: unmet needs of current treatments; treatmentresistant depression; bipolar depression; CIAS; line extensions.
Challenges in psychiatric diseases: availability of generics; PCP versus specialist prescribing; reimbursement issues.

Mentioned in This Report

Addiction
Attention-defi cit hyperactivity disorder
Bipolar disorder
Generalized anxiety disorder
Major depressive disorder
Panic disorder
Schizophrenia
Social anxiety disorder

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
The Psychiatric Disease Pipeline by the Numbers
Companies Developing Psychiatric Disease Agents
- GlaxoSmithKline
- AstraZeneca
Opportunities and Challenges in the Psychiatric Disease Market
- Important Market Opportunities for Psychiatric Diseases
  - High Unmet Need for Treatment-Resistant and Bipolar Depression
  - Cognitive Impairment Associated with Schizophrenia
- Challenges Facing Companies with Emerging Psychiatric Agents
  - Increased Treatment by PCPs Challenges Emerging Therapy Uptake
  - Reimbursement Issues Loom Large for Existing and New Agents Alike
Outlook: Strategies for Developers in a Challenging Sector
- Current Market Statistics
- Strategies for Emerging Agents

Tables

1. Psychiatric Disease Descriptions
2. Drug Classes Commonly Prescribed to Treat Psychiatric Disease
3. Unmet Needs in Psychiatric Disease
4. GlaxoSmithKline' s Psychiatric Pipeline
5. AstraZeneca' s Psychiatric Pipeline
6. Agents in Development for the Treatment of Cognitive Impairment Associated with Schizophrenia
7. Top-Selling Psychiatric Drugs, 2008